Amgen (AMGN) Boosts Cytokinetics (CYTK) to 7.58%
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Join SI Premium – FREE
In a 13D filed after markets closed, Amgen (Nasdaq: AMGN) disclosed an increased stake in Cytokinetics, Inc. (Nasdaq: CYTK).
Amgen reported holding 11,909,406 shares of Cytokinetics, or 7.58 percent of all outstanding, up from 3,484,806 shares reported on March 21, 2013.
Cytokinetics is up over 3 percent Tuesday night.
Amgen reported holding 11,909,406 shares of Cytokinetics, or 7.58 percent of all outstanding, up from 3,484,806 shares reported on March 21, 2013.
Cytokinetics is up over 3 percent Tuesday night.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
- Ionis to present olezarsen and ION775 data at ESC Congress 2026
- Harrow study shows Iheezo cuts discomfort after eye injections
Create E-mail Alert Related Categories
13Ds, FDA, Mergers and AcquisitionsRelated Entities
13DSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
